[ CAS No. 676371-00-9 ] {[proInfo.proName]}

Name: 676371-00-9|6-Bromoimidazo[1,2-a]pyridin-8-amine|98%
Brand: Ambeed
SKU: A273004
Price: 12.0 USD
Availability: InStock
Rating: 90 (30 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 676371-00-9

Structure of 676371-00-9 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 676371-00-9 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 676371-00-9 ]

SDS Specification

Alternatived Products of [ 676371-00-9 ]

Product Details of [ 676371-00-9 ]

CAS No. :	676371-00-9	MDL No. :	MFCD13250043
Formula :	C₇H₆BrN₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	NBHRWSCVWCCKDN-UHFFFAOYSA-N
M.W :	212.05	Pubchem ID :	17750394
Synonyms :

Calculated chemistry of [ 676371-00-9 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	1.0
Num. H-bond donors :	1.0
Molar Refractivity :	47.3
TPSA :	43.32 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.34 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.6
Log Po/w (XLOGP3) :	1.77
Log Po/w (WLOGP) :	1.69
Log Po/w (MLOGP) :	0.87
Log Po/w (SILICOS-IT) :	0.9
Consensus Log Po/w :	1.37

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.88
Solubility :	0.283 mg/ml ; 0.00133 mol/l
Class :	Soluble
Log S (Ali) :	-2.3
Solubility :	1.07 mg/ml ; 0.00504 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.58
Solubility :	0.551 mg/ml ; 0.0026 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.85

Safety of [ 676371-00-9 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 676371-00-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 676371-00-9 ]
Downstream synthetic route of [ 676371-00-9 ]

[ 676371-00-9 ] Synthesis Path-Upstream 1~3

1
[ 38875-53-5 ]
[ 2032-35-1 ]
[ 676371-00-9 ]

Yield	Reaction Conditions	Operation in experiment
92%	Stage #1: With hydrogenchloride In 1,4-dioxane; water for 0.5 h; Heating / reflux Stage #2: With sodium hydrogencarbonate In 1,4-dioxane; water at 20℃; for 14 h; Heating / reflux	To a soln of [BROMOACETALDEHYDE] diethyl acetal (2.37 mL, 15.4 [MMOL)] in [DIOXANE/H20] (2: 1/15 mL) at rt was added conc. [HCI] (0.3 mL) and the mixture was refluxed for 30 min. The mixture was cooled to rt whereupon [NAHCO3] (2.6 g, 30.8 [MMOL)] was carefully added followed by dropwise addition of diamino derivative (1.5 g, 7.7 [MMOL)] in [DIOXANE/H20] (2: [1/15] mL). The resultant mixture was stirred at reflux for 14 h and was cooled to rt. The mixture was diluted with 1 M [NAOH] (30 mL) and was extracted with [CH2CI2] (3 x 35 mL). The organic layers were combined, washed with brine [(1] x 20 mL), dried [(NA2SO4),] filtered and concentrated under reduced pressure to afford 1.5 g (92percent) of the desired compound [[M +] H = 214. [0].]

Reference： [1] Patent: WO2004/26867, 2004, A2, . Location in patent: Page 32-33

2
[ 107-20-0 ]
[ 38875-53-5 ]
[ 676371-00-9 ]

Yield	Reaction Conditions	Operation in experiment
71%	With sodium hydrogencarbonate In ethanol; water for 17 h; Reflux	[0264] To a stuffed solution of compound I (50 g; 0.26 mol; 1 eq) in ethanol (2 L) was added sodium bicarbonate (46 g; 0.53 mol; 2 eq) and chloroacetaldehyde solution (—50percent aqueous solution, 86 mL; 0.66 mol; 2.5 eq) drop wise and the resulting mixture was heated at reflux for 17 h. The mixture was then evaporated to dryness and the pH was adjusted to 7 using ice-cold saturated aqueous NaHCO3 solution and solid NaHCO3. The organic components were extracted from the aqueous layer with ethyl acetate (3 x 1000 mL) and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and the solvent was removed in vacuo to obtain a dry residue which was purified by silica gel (230-400 mesh) column chromatography using 10-50percent ethyl acetate/hexanes as the eluent to afford the title compound (40 g, 71percent) as a brown solid. 1H NMR (DMSO-d6) ö 8.04 (s, 1H), 7.77 (s, 1H), 7.44 (s, 1H), 6.31 (s, 1H), 5.99 (s, 2H). LCMS: m/z = 212.0 [M+j, 214.0 [M+21, RT = 2.55 minutes, (Program P1, Column V).
40%	at 20℃; Reflux; Inert atmosphere	To a stirred solution of 5-bromopyridine-2,3-diamine (278 g, 1478 mmol) in isopropanol (2.2 L) at rt was added chloroacetaldehyde (255 g, 1626 mmol) in one portion. After stirring in an nitrogen atmosphere under reflux overnight, the mixture was stirred for an additional 60 min at rt. The suspension was filtered, and the remaining solid was washed with isopropanol and dried in vaccuo at 50° C. Redissolution in methanol and evaporation yielded 6-bromoimidazo[1,2-a]pyridin-8-amine as a brown solid (124 g, 40 3/4): ¹H-NMR (300 MHz, d₆-DMSO): δ =8.39 (2H), 8.12 (2H), 6.92 (1H) ppm.

Reference： [1] Patent: WO2015/95128, 2015, A1, . Location in patent: Paragraph 0262-0264; 0293-0295; 0318-0320; 0448-0450
[2] Patent: WO2012/136531, 2012, A1, . Location in patent: Page/Page column 86
[3] Patent: WO2009/77334, 2009, A1, . Location in patent: Page/Page column 86
[4] Journal of Medicinal Chemistry, 2015, vol. 58, # 1, p. 512 - 516

3
[ 38875-53-5 ]
[ 17157-48-1 ]
[ 676371-00-9 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 22, p. 6216 - 6219

[ 676371-00-9 ] Synthesis Path-Downstream 1~85

1
[ 38875-53-5 ]
[ 17157-48-1 ]
[ 676371-00-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 6216 - 6219

2
[ 676371-00-9 ]
[ 98-80-6 ]
C₁₃H₁₁N₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
91%	With potassium phosphate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; for 18h;Heating / reflux;	To a solution of bromo compound from Preparative Example 10 (1.0 g, 4.72 [MMOL)] in [DME/H2O] (4: 1; 25 ml total) at rt was added PhB (OH) 2 (1.2 g, 9.4 mmol), [K3PO4] (3.0 g, 14.2 [MMOL),] and Pd (PPh3) 4 (0.54 g, 0.47 [MMOL).] The mixture was heated at reflux for 18 h and was cooled to rt. EtOAc (30 mL) and water (10 mL) were added and the layers were separated. The aqueous layer was extracted with EtOAc (3 x 30 mL) and the organic layers were combined. The organic layer was washed with brine (1 x 25 mL), dried [(NA2SO4),] filtered, and concentrated under reduced pressure to afford a brown oil. The crude product was purified by prep TLC (10 x 1000 [ILM)] using [CH2CI2/MEOH] (25: 1) as eluant to afford 0.9 g (91%) of a brown solid [M + [H] = 209.0].

Reference： [1]Patent: WO2004/26867,2004,A2 .Location in patent: Page 35-36
[2]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 6216 - 6219

3
[ 872-85-5 ]
[ 676371-00-9 ]
[ 676370-49-3 ]

Yield	Reaction Conditions	Operation in experiment
37%		To a solution of aniline (0.10 g, 0.47 [MMOL)] from Preparative Example 10 in [MEOH] (3 mL) at rt was added 4-pyridinecarboxyaldehyde (55 [No.L, ] 0.59 [MMOL)] and [ZNCI2] (112 mg, 0.82 [MMOL).] The resultant mixture was stirred for [1H] whereupon NaCNBH3 (37 mg, 0.59 [MMOL)] was added in one portion. The mixture was stirred at reflux for 14 h, cooled to rt, and concentrated under reduced pressure. The crude material was partitioned between [CH2CI2] (7 mL) and 2M [NAOH] (3 mL) and the layers were separated. The aqueous layer was extracted with [CH2CI2] (2 x 7 mL) and the organic layers were combined. The organic layer was dried [(NA2SO4),] filtered and concentrated under reduced pressure. The crude material was purified by prep TLC (6 x 1000 [P1M)] using [CH2CI2/MEOH] (20: 1) as eluant to afford 52 mg (37%) of a red-brown solid [M+H = 305.0] ; mp 167-172 [C.]

Reference： [1]Patent: WO2004/26867,2004,A2 .Location in patent: Page 33-34

4
[ 676371-00-9 ]
[ 34619-03-9 ]
C₁₂H₁₄BrN₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; triethylamine;	Treatment of aniline derivative from Preparative Example 10 under standard conditions [(BOC20,] [ET3N,] DMAP) affords the corresponding carbamate derivative

Reference： [1]Patent: WO2004/26867,2004,A2 .Location in patent: Page 54-55

5
[ 38875-53-5 ]
[ 2032-35-1 ]
[ 676371-00-9 ]

Yield	Reaction Conditions	Operation in experiment
92%		To a soln of [BROMOACETALDEHYDE] diethyl acetal (2.37 mL, 15.4 [MMOL)] in [DIOXANE/H20] (2: 1/15 mL) at rt was added conc. [HCI] (0.3 mL) and the mixture was refluxed for 30 min. The mixture was cooled to rt whereupon [NAHCO3] (2.6 g, 30.8 [MMOL)] was carefully added followed by dropwise addition of diamino derivative (1.5 g, 7.7 [MMOL)] in [DIOXANE/H20] (2: [1/15] mL). The resultant mixture was stirred at reflux for 14 h and was cooled to rt. The mixture was diluted with 1 M [NAOH] (30 mL) and was extracted with [CH2CI2] (3 x 35 mL). The organic layers were combined, washed with brine [(1] x 20 mL), dried [(NA2SO4),] filtered and concentrated under reduced pressure to afford 1.5 g (92%) of the desired compound [[M +] H = 214. [0].]

Reference： [1]Patent: WO2004/26867,2004,A2 .Location in patent: Page 32-33

6
[ 75-44-5 ]
[ 676371-00-9 ]
[ 74-89-5 ]
[ 1161847-37-5 ]

Yield	Reaction Conditions	Operation in experiment
		Example 25.; To 6-Bromo-imidazo[l,2-a]pyridin-8-ylamine (1.045g, 4.93mmol) in THF (100 mL) was added diisopropylethylamine (1.7mL, 2.5eq), and the resulting mixture was cooled to O0C. With stirring, a solution of 20% phosgene in toluene (3.1 ImL, 1.2eq) was added and the resulting mixture was stirred at O0C for 20 minutes. Next, a 2.0M solution of methylamine in THF (24.6mL, 10 eq) was added and the resulting mixture was stirred from O0C to RT overnight. Then next day, the solvent was removed under reduced pressure at 550C, and ethyl acetate (175 mL) and water (50 mL) were added. The resulting mixture was stirred vigorously for 10 minutes and then the layers were separated. The organic layer was dried over magnesium sulfate, filtered and concentrated to give 1- (6-Bromo-imidazo[l,2-a]pyridin-8-yl)-3-methyl-urea as an off-white foamy powder (1.074g).

Reference： [1]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 90

7
[ 75-44-5 ]
[ 676371-00-9 ]
[ 141-43-5 ]
[ 1161847-62-6 ]

Yield	Reaction Conditions	Operation in experiment
68%		Example 31.; Procedure for ethanolamine urea formation; To 50.0 mg (0.236 mmol) 6-Bromo-imidazo[l,2-alpha]pyridin-8-ylamine and 82.2 ul (0.59 mmol; 2.5 eq.) Net3 in 3.0 ml dichloromethane was added 148.0 ul (0.285 mmol; 1.2 eq.) 20% phosgene in toluene solution at 00C. The orange solution was stirred at 00C for 10 min., then 71.2 ul (1.18 mmol; 5.0 eq.) ethanolamine was added at once at the resulting reaction mixture was continued stirring at 00C for 10 min. ~ 5g silica gel was added and the slurry was evaporated. Residue was chromatographed over a 12g RediSep column, Hexane:AcOEt 0-100% in 15 min. To give: 45.8 mg of l-(6-Bromo-imidazo[l,2- a]pyridin-8-yl)-3-(2-hydroxy-ethyl)-urea as an off-white solid. Yield = 68%

Reference： [1]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 92

8
[ 75-44-5 ]
[ 676371-00-9 ]
[ 1161847-38-6 ]

Yield	Reaction Conditions	Operation in experiment
56%		Example 27.; 6-Bromo-imidazo[l,2-a]pyridine-8-ylamine (0.75 G, 0.0035 moles) and DIEA (1.35 g, 0.0104 moles) were placed in 50 ml dichloromethane. After cooling the mixture to 00C, a <n="92"/>20% phosgene solution in toluene was added (2.5 ml, 0.0051 moles). The reaction mixture was stirred 1 hour at 00C and then ammonia 0.5M in dioxane (70 ml, 0.035 moles) was added. After stirring 4 hours at RT the mixture was concentrated in vacuo and the residue extracted with ethylacetate - 200 ml. This solution was washed with brine, dried over sodium sulfate, concentrated in vacuo, then further dried in h.v. to give 0.5 g of (6- Bromo-imidazo[l,2-a]pyridin-8-yl)-urea ( yield 56%).

Reference： [1]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 90-91

9
[ 107-20-0 ]
[ 38875-53-5 ]
[ 676371-00-9 ]

Yield	Reaction Conditions	Operation in experiment
71%	With sodium hydrogencarbonate; In ethanol; water; for 17h;Reflux;	[0264] To a stuffed solution of compound I (50 g; 0.26 mol; 1 eq) in ethanol (2 L) was added sodium bicarbonate (46 g; 0.53 mol; 2 eq) and chloroacetaldehyde solution (-50% aqueous solution, 86 mL; 0.66 mol; 2.5 eq) drop wise and the resulting mixture was heated at reflux for 17 h. The mixture was then evaporated to dryness and the pH was adjusted to 7 using ice-cold saturated aqueous NaHCO3 solution and solid NaHCO3. The organic components were extracted from the aqueous layer with ethyl acetate (3 x 1000 mL) and the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and the solvent was removed in vacuo to obtain a dry residue which was purified by silica gel (230-400 mesh) column chromatography using 10-50% ethyl acetate/hexanes as the eluent to afford the title compound (40 g, 71%) as a brown solid. 1H NMR (DMSO-d6) oe 8.04 (s, 1H), 7.77 (s, 1H), 7.44 (s, 1H), 6.31 (s, 1H), 5.99 (s, 2H). LCMS: m/z = 212.0 [M+j, 214.0 [M+21, RT = 2.55 minutes, (Program P1, Column V).
40%	In isopropyl alcohol; at 20℃;Reflux; Inert atmosphere;	To a stirred solution of 5-bromopyridine-2,3-diamine (278 g, 1478 mmol) in isopropanol (2.2 L) at rt was added chloroacetaldehyde (255 g, 1626 mmol) in one portion. After stirring in an nitrogen atmosphere under reflux overnight, the mixture was stirred for an additional 60 min at rt. The suspension was filtered, and the remaining solid was washed with isopropanol and dried in vaccuo at 50 C. Redissolution in methanol and evaporation yielded 6-bromoimidazo[1,2-a]pyridin-8-amine as a brown solid (124 g, 40 ¾): 1H-NMR (300 MHz, d6-DMSO): delta =8.39 (2H), 8.12 (2H), 6.92 (1H) ppm.
	In water; isopropyl alcohol; for 24h;Heating / reflux;	Example 15.; 2,3-diamino-5-bromopyridine (10. Og, 45.86mmol) was dissolved in 80ml of IPA and then 50% wt chloroacetaldehyde/eta2theta (6.51ml, 50.45mmol) was added. The resulting mixture was heated at reflux for 24 hrs. The mixture was cooled down and then filtered. The cake was dried to afford 9.10 g of 6-Bromo-imidazo[l,2-a]pyridin-8-ylamine.

Reference： [1]Patent: WO2015/95128,2015,A1 .Location in patent: Paragraph 0262-0264; 0293-0295; 0318-0320; 0448-0450
[2]Patent: WO2012/136531,2012,A1 .Location in patent: Page/Page column 86
[3]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 86
[4]Journal of Medicinal Chemistry,2015,vol. 58,p. 512 - 516

10
[ 64614-49-9 ]
[ 676371-00-9 ]
[ 1161847-57-9 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium tert-butylate; In 1,4-dioxane; at 150℃; for 0.333333h;Microwave irradiation;	Example 45.; 4.5g (21 mmol) of 6-Bromo-imidazo[l,2-a]pyridine-8-yl-amine, 5.29g (23 mmol) of (6- Chloropyridine-3-yl) morphilin-4-yl-methanone and 4.76g (43 mmol) of potassium tert- butoxide were dissolved in 20 ml dioxane. This suspension was heated for 20 min at 1500C in the microwave. The reaction mixture was concentrated. The residue was diluted with dichloromethane. Deionized water was added and the basic water phase was neutralized with an 1 N HCl solution. An excess of sodium sulfate was added and stirred for a while. The slimy mixture was filtered over a plug of celite. The filtrate was extracted with dichloromethane; org. phase was dried over sodium sulfate; filtered; concentrated. This residue was purified by a 20Og silica gel column with the solvent ethyl acetate for 15 min, then dichloromethane for 20 min, then 0-10% Methanol in dichloromethane during 40 min. 4.66 g of a light brown foam was obtained. LCMS: M(H+)= 402.

Reference： [1]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 100
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 512 - 516

11
[ 676371-00-9 ]
[ 910235-65-3 ]
[ 1161846-73-6 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; at 170℃; for 0.333333h;Microwave irradiation;	Example 19.; A mixture of 6-Bromo-imidazo[l,2-a]pyridin-8-ylamine (0.72g, 3.43mmol), 4-tert-Butyl- N-[2-methyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolane-2-yl)-phenyl]-benzamide (1.0g, 2.54 mmol), Pd(PPh3)4 (0.29g, 0.25 mmol) in 5ml IM Na2CO3 and 10 mL of ethylene glycol dimethyl ether was stirred at 1700C in a microwave for 20 min. The resulting suspension was filtered through celite and then partitioned between 100 mL of water and 100 mL of ethyl acetate, and the aqueous layer was further extracted with 50 mL of ethyl acetate. The combined organic layers were dried over MgSO4, filtered, and concentrated to a residue. Column chromatography (0-6% MeOH/CH2Cl2) afforded 0.685 g of N-[3- (8-Amino-imidazo[l,2-a]pyridin-6-yl)-2-methyl-phenyl]-4-tert-butyl-benzamide.

Reference： [1]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 87
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 512 - 516

12
[ 676371-00-9 ]
[ 1161847-42-2 ]
[ 1161847-43-3 ]

Yield	Reaction Conditions	Operation in experiment
63%	With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; at 110℃; for 0.5h;Microwave irradiation;	B. Pyrrolidine- 1-carboxylic acid [3-(8-amino-imidazo[l,2-a]pyridin-6-yl)-2-methyl- phenyl] -amide; The mixture of 105 mg (0.493 mmol) of 6-Bromo-imidazo[l,2-a]pyridin-8-ylamine, 195 mg (0.591 mmol) of Pyrrolidine- 1-carboxylic acid [2-methyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenyl]-amide, 157 mg (1.48 mmol) of sodium carbonate, and 57 mg (0.049 mmol) of tetrakis(triphenylphosphine)palladium in 5 mL of 1,2- dimethoxyethane and 2.5 mL of water was heated at 1100C for 30 minutes using microwave. The mixture was partitioned between 50 mL of ethyl acetate and 10 mL of water. The organic layer was dried (MgSO4), and concentrated. Column chromatography (0 -> 10% MeOH/CH2Cl2 in 20 minutes) gave 104 mg (0.310 mmol, 63%) of the title compound.

Reference： [1]Patent: WO2009/77334,2009,A1 .Location in patent: Page/Page column 94

13
[ 676371-00-9 ]
[ 460-40-2 ]
[ 1402595-23-6 ]

Yield	Reaction Conditions	Operation in experiment
52%	With sodium tris(acetoxy)borohydride; acetic acid; In dichloromethane; at 23℃; for 3h;	To a mixture comprising 21.7 g (102.3 mmol) 6-bromoimidazo[1 ,2-a]pyridin-8- amine which was prepared according to intermediate example 3-1 , 13.05 mL 3,3,3- trifluoropropanal, 18.16 mL acetic acid in 1 .3 L dichloromethane were added a total of 65.07 g sodium tris(acetato-kappaO)(hydrido)borate(1 -) in portions. After the mixture was stirred at 23C for 3 hours it was cooled to 3C and 300 mL 4M aqueous ammonia was carefully added. The mixture was extracted withdichloromethane, the organic layer washed with brine and dried over sodium sulfate. After filtration and removal of solvent the residue was purified by chromatography to give 16.26 g (52%) of the title compound.

Reference： [1]Patent: WO2012/136531,2012,A1 .Location in patent: Page/Page column 101

14
[ 676371-00-9 ]
[ 430-69-3 ]
[ 1402596-19-3 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium tris(acetoxy)borohydride; trifluoroacetic acid; In dichloromethane; at 20℃; for 72h;	To a solution of 8.00 g (100 mmol) freshly prepared difluoroacetaldehyde in 560 mL DCM was added 5.30 g (25 mmol) 6-bromoimidazo[1 ,2-a]pyridin-8-amine, 26.49 g (125 mmol) sodium triacetoxy borohydride and 28.5 g (18.56 mL, 250 mmol) TFA and the mixture was stirred for 72 h at rt to give, after working up andpurification, 4.0 g (58 ¾) of the title compound. UPLC MS: RT = 0.71 min; m/z (ES+) 277.1 [MH+]; required MW = 276.1. 1 H-NMR (300 MHz ,DMSO-d6), delta [ppm]= 3.69 (2H), 6.36 (1 H), 6.54 (1 H), 7.41 (1 H), 7.77 (1 H), 8.10 (1 H).

Reference： [1]Patent: WO2012/136531,2012,A1 .Location in patent: Page/Page column 229-230

15
[ 676371-00-9 ]
[ 1402593-77-4 ]

Reference： [1]Patent: WO2012/136531,2012,A1

16
[ 676371-00-9 ]
[ 1402595-16-7 ]

Yield	Reaction Conditions	Operation in experiment
78.2%	With N-iodo-succinimide; In tetrahydrofuran; at 0℃;	To a stirred suspension of 6-bromoimidazo[1 ,2-a]pyridin-8-amine (20.6 g, 97.15 mmol) in THF 100 mL) at 0C was dropwise added a solution of NIS (25.4 g, 112.87 mmol, 1.16 eq) in 215 mL THF. After stirring for 2h, isolute sorbent (Biotage) was added (20 g) and the mixture was evaporated in vaccuo. The residue was loaded on a flash column and the crude product purified by flash chromatography (ethyl acetate / hexane) to yield 25.6 g 6-bromo-3-iodoimidazo[1,2-a]pyridin-8-amine (78.2 %).1H-NMR (300 MHz, d6-DMSO): delta = 7.60 (1H), 7.54 (1H, d), 6.38 (1H), 6.12 (2H) ppm. UPLC-MS: RT = 0.98 min; m/z (ES+) 339.0 [MH+]; required MW = 338.0.

Reference： [1]Patent: WO2012/136531,2012,A1 .Location in patent: Page/Page column 86-87

17
[ 676371-00-9 ]
[ 1402595-18-9 ]

Reference： [1]Patent: WO2012/136531,2012,A1

18
[ 676371-00-9 ]
[ 1402594-63-1 ]

Reference： [1]Patent: WO2012/136531,2012,A1

19
[ 676371-00-9 ]
[ 1402595-17-8 ]

Reference： [1]Patent: WO2012/136531,2012,A1

20
[ 676371-00-9 ]
[ 1402594-95-9 ]

Reference： [1]Patent: WO2012/136531,2012,A1

21
[ 676371-00-9 ]
[ 1402596-15-9 ]

Reference： [1]Patent: WO2012/136531,2012,A1

22
[ 676371-00-9 ]
[ 1402596-16-0 ]

Reference： [1]Patent: WO2012/136531,2012,A1

23
[ 676371-00-9 ]
[ 1402596-17-1 ]

Reference： [1]Patent: WO2012/136531,2012,A1

24
[ 676371-00-9 ]
[ 1402596-18-2 ]

Reference： [1]Patent: WO2012/136531,2012,A1

25
[ 676371-00-9 ]
[ 1402593-27-4 ]

Reference： [1]Patent: WO2012/136531,2012,A1

26
[ 676371-00-9 ]
[ 1402593-29-6 ]

Reference： [1]Patent: WO2012/136531,2012,A1

27
[ 676371-00-9 ]
[ 1402593-35-4 ]

Reference： [1]Patent: WO2012/136531,2012,A1

28
[ 676371-00-9 ]
[ 1402593-36-5 ]

Reference： [1]Patent: WO2012/136531,2012,A1

29
[ 676371-00-9 ]
[ 1402593-37-6 ]

Reference： [1]Patent: WO2012/136531,2012,A1

30
[ 676371-00-9 ]
[ 1402593-38-7 ]

Reference： [1]Patent: WO2012/136531,2012,A1

31
[ 676371-00-9 ]
[ 1402595-20-3 ]

Reference： [1]Patent: WO2012/136531,2012,A1

32
[ 676371-00-9 ]
[ 1402595-21-4 ]

Reference： [1]Patent: WO2012/136531,2012,A1

33
[ 676371-00-9 ]
[ 1402595-22-5 ]

Reference： [1]Patent: WO2012/136531,2012,A1

34
[ 676371-00-9 ]
[ 910235-65-3 ]
[ 1161846-71-4 ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 512 - 516

35
[ 67-56-1 ]
[ 676371-00-9 ]
[ 201230-82-2 ]
8-aminoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65%	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; N-ethyl-N,N-diisopropylamine; at 90℃; under 2585.81 Torr; for 16h;Autoclave; Inert atmosphere;	[0541] To a solution of compound 11(6 g, 28 mmol, 1 eq) in MeOH (100 mL) was added DIPEA (26 mL, 140 mmol, 5 eq) and the resulting mixture was degassed with argon for 10 mm, then PdC12(dppf).CH2C12 (2.3 g, 2.8 mol, 0.1 eq) was added. Degassing with argon was repeated for 10 mm and the reaction vessel was attached to Parr autoclave stirring at 90 C at 50 psi under CO atmosphere for 16 h. The mixture was filtered through a Celite pad and the filtrate was concentrated in vacuo to obtain a solid residue. The residue was then washed with water (100 mL) and the organic components were extracted with ethyl acetate (800 mL), dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure to provide crude compound. The crude product was purified by flash CombiflashTM chromatography using 100-200 mesh silica gel eluting with 40% EtOAc/hexanes to obtain the title compound (3.5g, 65%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) oe 8.57 (d, 1H, J = 1 Hz), 7.97 (s, 1H), 7.51 (s, 1H), 6.67 (d, 1H), 5.87 (s, 2H), 3.84 (s, 3H). LCMS:mlz = 191.8 [M + HI, RT = 0.78 minutes; (Program Ri, Column Y).

Reference： [1]Patent: WO2015/95128,2015,A1 .Location in patent: Paragraph 0537; 0540 0541

36
[ 676371-00-9 ]
8-[bis-(tert-butoxycarbonyl)amino]imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

37
[ 676371-00-9 ]
3-bromo-8-[bis-(tert-butoxycarbonyl)amino]imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

38
[ 676371-00-9 ]
8-amino-3-bromoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

39
[ 676371-00-9 ]
3-bromo-8-[1-dimethylaminoethylideneamino]imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

40
[ 676371-00-9 ]
3-bromo-8-(2,5-dimethylimidazol-1-yl)imidazo-[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

41
[ 676371-00-9 ]
8-(2,5-dimethylimidazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

42
[ 676371-00-9 ]
8-(2,5-dimethylimidazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

43
[ 676371-00-9 ]
8-(2,5-dimethyl-1H-imidazol-1-yl)-N-((6-methylpyridin-3-yl)methyl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

44
[ 676371-00-9 ]
3-bromo-8-(3,5-dimethyl-[1,2,4]triazol-4-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

45
[ 676371-00-9 ]
8-(3,5-dimethyl-[1,2,4]triazol-4-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

46
[ 676371-00-9 ]
8-(3,5-dimethyl-[1,2,4]triazol-4-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

47
[ 676371-00-9 ]
(S)-N-(1-(4H-1,2,4-triazol-3-yl)ethyl)-8-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

48
[ 676371-00-9 ]
8-azidoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

49
[ 676371-00-9 ]
8-(5-difluoromethyl-4-ethoxycarbonyl-[1,2,3]triazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

50
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyl-4-ethoxycarbonyl-[1,2,3]triazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

51
[ 676371-00-9 ]
3-bromo-8-(4-carboxy-5-difluoromethyl-[1,2,3]triazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

52
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyl-[1,2,3]triazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

53
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyl-[1,2,3]triazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [(S)-1-(4H-[1,2,4]triazol-3-yl)ethyl]amide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

54
[ 676371-00-9 ]
(S)-N-(1-(4H-1,2,4-triazol-3-yl)ethyl)-8-(5-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

55
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyl-[1,2,3]triazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid (6-methylpyridin-3-ylmethyl)amide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

56
[ 676371-00-9 ]
8-(5-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-3-(5-methyl-1,3,4-thiadiazol-2-yl)-N-((6-methylpyridin-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

57
[ 676371-00-9 ]
3-bromo-8-hydrazinoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

58
[ 676371-00-9 ]
3-bromo-8-(3-ethoxycarbonyl-5-ethylpyrazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

59
[ 676371-00-9 ]
8-(3-ethoxycarbonyl-5-ethylpyrazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

60
[ 676371-00-9 ]
8-(3-carboxy-5-ethylpyrazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

61
[ 676371-00-9 ]
8-(5-ethylpyrazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

62
[ 676371-00-9 ]
8-(5-ethyl-1H-pyrazol-1-yl)-N-((6-methylpyridin-3-yl)methyl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

63
[ 676371-00-9 ]
8-(5-difluoromethyl-4-ethoxycarbonyl-[1,2,3]triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

64
[ 676371-00-9 ]
8-(4-carboxy-5-difluoromethyl-[1,2,3]triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

65
[ 676371-00-9 ]
8-(5-difluoromethyl-[1,2,3]triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

66
[ 676371-00-9 ]
N’-((S)-2-[8-(5-difluoromethyl-[1,2,3]triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carbonyl]amino}propionyl)hydrazine carboxylic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

67
[ 676371-00-9 ]
8-(5-difluoromethyl-[1,2,3]triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid ((S)-1-hydrazinocarbonylethyl)amide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

68
[ 676371-00-9 ]
(S)-N-(1-(1,3,4-oxadiazol-2-yl)ethyl)-8-(5-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

69
[ 676371-00-9 ]
8-(2,2-difluoroacetylamino)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

70
[ 676371-00-9 ]
8-(5-difluoromethyltetrazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

71
[ 676371-00-9 ]
8-(2,2-difluorothioacetylamino)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

72
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyltetrazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

73
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyltetrazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

74
[ 676371-00-9 ]
3-bromo-8-(5-difluoromethyltetrazol-1-yl)imidazo[1,2-a]pyridine-6-carboxylic acid (6-methylpyridin-3-ylmethyl)amide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

75
[ 676371-00-9 ]
8-(5-(difluoromethyl)-1H-tetrazol-1-yl)-N-((6-methylpyridin-3-yl)methyl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

76
[ 676371-00-9 ]
8-(5-difluoromethyltetrazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

77
[ 676371-00-9 ]
8-(5-difluoromethyltetrazol-1-yl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

78
[ 676371-00-9 ]
(R)-8-(5-(difluoromethyl)-1H-tetrazol-1-yl)-N-(1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1
[2]Patent: WO2015/95128,2015,A1

79
[ 676371-00-9 ]
8-isobutyrylaminoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

80
[ 676371-00-9 ]
8-(isobutyryl-N-methylamino)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

81
[ 676371-00-9 ]
3-bromo-8-(isobutyryl-N-methylamino)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

82
[ 676371-00-9 ]
8-(isobutyryl-N-methylamino)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

83
[ 676371-00-9 ]
8-(isobutyryl-N-methylamino)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxylic acid [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

84
[ 676371-00-9 ]
(S)-N-(1-(4H-1,2,4-triazol-3-yl)ethyl)-8-(N-methylisobutyramido)-3-(5-methylthiophen-2-yl)imidazo[1,2-a]pyridine-6-carboxamide [ No CAS ]

Reference： [1]Patent: WO2015/95128,2015,A1

85
[ 676371-00-9 ]
[ 75-36-5 ]
N-(6-bromoimidazo[1,2-a]pyridin-8-yl)acetamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
41.7%	With pyridine; In dichloromethane; at 0 - 20℃; for 12h;	To a solution of 22A (0.3 g, 1.415 mmol) in dry DCM (8 mL) at 0 C was added pyridine(0.172 mL, 2.122 mmol), followed by adropwise addition of AcC1 (0.121 mL,1.698 mmol). The resulting mixture was stirred at RT for 12 h. The reaction mixture was diluted with DCM (50 mL) and washed with saturated aq. NaHCO3 solution, dried over anhydrous Na2SO4, filtered and the filtrate evaporated under reduced pressure to get the crude residue. The cmde product was purified by silica gel chromatography (40 g RediSep column, eluting with a gradient of 30-50 % EtOAc in petroleum ether).Fractions containing the desired product were combined and evaporated under reduced pressure to afford intermediate 22B (0.15 g, 41.7 % yield). LCMS: m/z 256.0 [M+2j HPLC Ret. Time 1.423 (HPLC Method E).

Reference： [1]Patent: WO2018/17633,2018,A1 .Location in patent: Page/Page column 91

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 676371-00-9 ]

Bromides

[ 6188-23-4 ]

6-Bromoimidazo[1,2-a]pyridine

Similarity: 0.87

[ 808744-34-5 ]

7-Bromoimidazo[1,2-a]pyridine

Similarity: 0.80

[ 116355-18-1 ]

6-Bromo-7-methylimidazo[1,2-a]pyridine

Similarity: 0.79

[ 30384-96-4 ]

6-Bromoimidazo[1,2-a]pyridine-3-carbaldehyde

Similarity: 0.79

[ 2044706-79-6 ]

6-Bromoimidazo[1,2-a]pyridine-3-carboxamide

Similarity: 0.79

Amines

[ 73221-18-8 ]

Imidazo[1,2-a]pyridin-8-ylamine

Similarity: 0.85

[ 2044706-79-6 ]

6-Bromoimidazo[1,2-a]pyridine-3-carboxamide

Similarity: 0.79

[ 947248-52-4 ]

6-Bromoimidazo[1,2-a]pyridin-2-amine

Similarity: 0.78

[ 173159-45-0 ]

2-Methylimidazo[1,2-a]pyridin-8-ylamine hydrochloride

Similarity: 0.78

[ 89415-54-3 ]

5-Bromo-N2-methylpyridine-2,3-diamine

Similarity: 0.77

Related Parent Nucleus of
[ 676371-00-9 ]

Other Aromatic Heterocycles

[ 6188-23-4 ]

6-Bromoimidazo[1,2-a]pyridine

Similarity: 0.87

[ 73221-18-8 ]

Imidazo[1,2-a]pyridin-8-ylamine

Similarity: 0.85

[ 808744-34-5 ]

7-Bromoimidazo[1,2-a]pyridine

Similarity: 0.80

[ 116355-18-1 ]

6-Bromo-7-methylimidazo[1,2-a]pyridine

Similarity: 0.79

[ 30384-96-4 ]

6-Bromoimidazo[1,2-a]pyridine-3-carbaldehyde

Similarity: 0.79

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 676371-00-9 ] {[proInfo.proName]}

Quality Control of [ 676371-00-9 ]

Related Doc. of [ 676371-00-9 ]

Product Details of [ 676371-00-9 ]

Calculated chemistry of [ 676371-00-9 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 676371-00-9 ]

Application In Synthesis of [ 676371-00-9 ]

[ 676371-00-9 ] Synthesis Path-Upstream 1~3

[ 676371-00-9 ] Synthesis Path-Downstream 1~85

Related Functional Groups of [ 676371-00-9 ]

Bromides

Amines

Related Parent Nucleus of [ 676371-00-9 ]

Other Aromatic Heterocycles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 676371-00-9 ]

Related Parent Nucleus of
[ 676371-00-9 ]